{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:49:03Z","timestamp":1791643743987,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jacc.2020.12.057","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T16:25:52Z","timestamp":1614615952000},"page":"1211-1221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Spironolactone in Patients With Heart\u00a0Failure, Preserved Ejection Fraction, and Worsening Renal Function"],"prefix":"10.1016","volume":"77","author":[{"given":"Iris E.","family":"Beldhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder L.","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome L.","family":"Fleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"McKinlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.12.057_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: heart disease and stroke statistics-2016 update: A Report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.057_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.12.057_bib3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ejhf.609","article-title":"Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme","volume":"18","author":"Damman","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib5","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.057_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.057_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2020.12.057_bib12","first-page":"25","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2020.12.057_bib13","first-page":"1342","article-title":"2017 comprehensive update of the Canadian Cardiovascular Society Guidelines for the Management of Heart\u00a0Failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib14","first-page":"180","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Basic to Transl Sci"},{"key":"10.1016\/j.jacc.2020.12.057_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) [erratum]","volume":"7","year":"2017","journal-title":"Ki Kidney Int Suppl"},{"key":"10.1016\/j.jacc.2020.12.057_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: an update","volume":"36","author":"Damman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.12.057_bib17","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.686","article-title":"Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT","volume":"19","author":"Bristow","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijcard.2009.09.529","article-title":"Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction","volume":"147","author":"Rusinaru","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib20","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2020.12.057_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.057_bib23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/eurjhf\/hft089","article-title":"Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: Insights from the Val-HeFT study","volume":"15","author":"Lesogor","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0002-9149(92)90683-P","article-title":"Effects of enalapril on long-term mortality in severe congestive heart failure","volume":"69","author":"Kjekshus","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejhf.13","article-title":"Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction","volume":"16","author":"Clark","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Ren Fail"},{"key":"10.1016\/j.jacc.2020.12.057_bib28","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.057_bib29","article-title":"Mechanistic effects of spironolactone on cardiovascular and renal biomarkers in heart failure with\u00a0preserved ejection fraction: a TOPCAT Biorepository Study","volume":"13","author":"Myhre","year":"2020","journal-title":"Circ Hear Fail"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:14Z","timestamp":1760017154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0735109721000140"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.057","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone in Patients With Heart\u00a0Failure, Preserved Ejection Fraction, and Worsening Renal Function","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}